PubRank

M F Brady

Author PubWeight™ 57.60‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 11.72
2 Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000 4.48
3 Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993 2.96
4 The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994 2.50
5 Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991 2.13
6 Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996 1.91
7 Simultaneously detected endometrial and ovarian carcinomas--a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001 1.70
8 Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996 1.66
9 Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999 1.66
10 Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 2007 1.53
11 Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 1998 1.27
12 Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 1995 1.23
13 Adenosarcoma of the uterus: a Gynecologic Oncology Group clinicopathologic study of 31 cases. Int J Gynecol Pathol 1992 1.19
14 The MIT D-lab electricity-free PortaTherm™ incubator for remote testing with the QuantiFERON®-TB Gold In-Tube assay. Int J Tuberc Lung Dis 2010 1.11
15 Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001 1.09
16 Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol 1998 1.09
17 Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 2001 1.07
18 Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993 1.04
19 Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983 1.04
20 Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999 1.02
21 High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1996 1.00
22 Frictional properties of Hartley guinea pig knees with and without proteolytic disruption of the articular surfaces. Osteoarthritis Cartilage 2006 1.00
23 Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985 0.96
24 Clinical trials in ovarian carcinoma: study methodology. Ann Oncol 2005 0.90
25 Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995 0.88
26 Surgical staging of carcinoma of the ovaries. Surg Gynecol Obstet 1989 0.88
27 The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol 1999 0.84
28 Reducing the string test intra-gastric downtime for detection of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008 0.81
29 Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study. Semin Oncol 1997 0.79
30 Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J Urol 1983 0.78
31 Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1993 0.78
32 Maintenance chemotherapy in advanced ovarian cancer. J Clin Oncol 2000 0.77
33 Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol 2011 0.77
34 A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area. J Urol 1983 0.76
35 Stable versus partial response in advanced prostate cancer. Prostate 1984 0.76
36 The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 1980 0.76
37 A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol 1992 0.76
38 A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1990 0.76
39 [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. Gynecol Obstet Fertil 2000 0.76
40 Observations of prolonged use of oral Emcyt in prostatic cancer patients. Urology 1982 0.75
41 Prostatic carcinoma treated at a categorical center, 1970--1979. N Y State J Med 1983 0.75
42 A reexamination of the stable category for evaluating response in patients with advanced prostate cancer. Cancer 1984 0.75
43 The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. J Surg Oncol 1983 0.75
44 Localized ovarian cancer in the elderly. The Gynecologic Oncology Group experience. Cancer 1993 0.75